Difference between revisions of "Chronic myeloid leukemia, pediatric"
Jump to navigation
Jump to search
m |
|||
Line 10: | Line 10: | ||
=="How I Treat"== | =="How I Treat"== | ||
*'''2019:''' Hijiya & Suttorp [http://www.bloodjournal.org/content/133/22/2374.long How I treat chronic myeloid leukemia in children and adolescents] | *'''2019:''' Hijiya & Suttorp [http://www.bloodjournal.org/content/133/22/2374.long How I treat chronic myeloid leukemia in children and adolescents] | ||
− | = | + | =COGAAML0123= |
==Stratum 1, 2, or 3== | ==Stratum 1, 2, or 3== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" |
Revision as of 16:07, 22 January 2022
Section editor transclusions This page contains studies that were specific to pediatric populations. For the more general CML page, follow this link.
6 regimens on this page
7 variants on this page
|
Guidelines
"How I Treat"
- 2019: Hijiya & Suttorp How I treat chronic myeloid leukemia in children and adolescents
COGAAML0123
Stratum 1, 2, or 3
back to top |
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Champagne et al. 2011 (COG AAML0123) | 2002-2004 | Phase II (RT) |
Chemotherapy
- Imatinib (Gleevec) 340 mg/m2 PO rounded to the nearest 100 mg once daily.
- Patient evaluated per protocol after each 28 day cycle for response and toxicities.
- Hold Imatinib (Gleevec) if a grade 2 nonhematologic adverse event fails to resolve or if a grade 3 or 4 nonhematologic adverse event occurs.
- After resolution to < grade 1, Imatinib (Gleevec) dose may be reduced by 30%.
- Imatinib (Gleevec) therapy continued until completion of 13 28-day courses (1 year).
28-Day Course
References
- COG AAML0123: Champagne MA, Fu CH, Chang M, Chen H, Gerbing RB, Alonzo TA, Cooley LD, Heerema NA, Oehler V, Wood C, French ME, Arceci RJ, Smith FO, Bernstein ML. Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011 Jul 15;57(1):56-62. Epub 2011 Apr 4. link to original article link to PMC article contains protocol PubMed NCT00030394
Stratum 4
back to top |
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Champagne et al. 2011 (COG AAML0123) | 2002-2004 | Phase II (RT) |
Chemotherapy
- Imatinib (Gleevec) 570 mg/m2/day PO divided BID rounded to the nearest 100 mg (maximum dose of 1000 mg/day).
- Patient evaluated per protocol after each 28 day cycle for response and toxicities.
- Hold Imatinib (Gleevec) if a grade 2 nonhematologic adverse event fails to resolve or if a grade 3 or 4 nonhematologic adverse event occurs.
- After resolution to < grade 1, Imatinib (Gleevec) dose may be reduced by 30%.
- Imatinib (Gleevec) therapy continued until completion of 13 28-day courses (1 year).
28-Day Course
References
- COG AAML0123: Champagne MA, Fu CH, Chang M, Chen H, Gerbing RB, Alonzo TA, Cooley LD, Heerema NA, Oehler V, Wood C, French ME, Arceci RJ, Smith FO, Bernstein ML. Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011 Jul 15;57(1):56-62. Epub 2011 Apr 4. link to original article link to PMC article contains protocol PubMed NCT00030394
AAML1321
Nilotinib monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Hijiya et al. 2019 (DIALOG) | 2013-2015 | Phase II (RT) |
Targeted therapy
- Nilotinib (Tasigna) 230 mg/m2 PO twice per day rounded to the nearest 50 mg dose (maximum single dose = 400 mg)
28-Day Course Up to 66 cycles
References
- DIALOG: Hijiya N, Maschan A, Rizzari C, Shimada H, Dufour C, Goto H, Kang HJ, Guinipero T, Karakas Z, Bautista F, Ducassou S, Yoo KH, Zwaan CM, Millot F, Aimone P, Allepuz A, Quenet S, Hourcade-Potelleret F, Hertle S, Sosothikul D. Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia. Blood. 2019 Dec 5;134(23):2036-2045. link to original article contains verified protocol link to PMC article PubMed NCT01844765
- Update: Hijiya N, Maschan A, Rizzari C, Shimada H, Dufour C, Goto H, Kang HJ, Guinipero T, Karakas Z, Bautista F, Ducassou S, Yoo KH, Zwaan CM, Millot F, Patterson B, Samis J, Aimone P, Allepuz A, Titorenko K, Sosothikul D. A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety. Blood Adv. 2021 Jul 27;5(14):2925-2934. link to original article contains verified protocol link to PMC article PubMed
Chronic phase, first-line therapy
Imatinib monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Champagne et al. 2011 (COG AAML0123) | 2002-2004 | Phase II (RT) |
Targeted therapy
- Imatinib (Gleevec) 340 mg/m2 PO once per day
28-day cycles
References
- COG AAML0123: Champagne MA, Fu CH, Chang M, Chen H, Gerbing RB, Alonzo TA, Cooley LD, Heerema NA, Oehler V, Wood C, French ME, Arceci RJ, Smith FO, Bernstein ML. Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011 Jul 15;57(1):56-62. Epub 2011 Apr 4. link to original article link to PMC article contains protocol PubMed NCT00030394
Nilotinib monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Hijiya et al. 2019 (DIALOG) | 2013-2015 | Phase II (RT) |
Targeted therapy
- Nilotinib (Tasigna) 230 mg/m2 PO twice per day
Continued indefinitely
References
- DIALOG: Hijiya N, Maschan A, Rizzari C, Shimada H, Dufour C, Goto H, Kang HJ, Guinipero T, Karakas Z, Bautista F, Ducassou S, Yoo KH, Zwaan CM, Millot F, Aimone P, Allepuz A, Quenet S, Hourcade-Potelleret F, Hertle S, Sosothikul D. Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia. Blood. 2019 Dec 5;134(23):2036-2045. link to original article contains verified protocol link to PMC article PubMed NCT01844765
Chronic phase, relapsed or refractory
Dasatinib monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Zwaan et al. 2013 (CA180-018) | 2006-2009 | Phase I, <20 pts in this cohort (RT) |
Gore et al. 2018 (CA180-226) | 2009-2014 | Phase II (RT) |
Targeted therapy
- Dasatinib (Sprycel) 60 mg/m2 PO once per day
Continued indefinitely
References
- CA180-018: Zwaan CM, Rizzari C, Mechinaud F, Lancaster DL, Lehrnbecher T, van der Velden VH, Beverloo BB, den Boer ML, Pieters R, Reinhardt D, Dworzak M, Rosenberg J, Manos G, Agrawal S, Strauss L, Baruchel A, Kearns PR. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. J Clin Oncol. 2013 Jul 1;31(19):2460-8. Epub 2013 May 28. link to original article PubMed NCT00306202
- CA180-226: Gore L, Kearns PR, de Martino Lee ML, De Souza CA, Bertrand Y, Hijiya N, Stork LC, Chung NG, Cardos RC, Saikia T, Fagioli F, Seo JJ, Landman-Parker J, Lancaster D, Place AE, Rabin KR, Sacchi M, Swanink R, Zwaan CM. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial. J Clin Oncol. 2018 May 1;36(13):1330-1338. Epub 2018 Mar 2. link to original article link to PMC article contains verified protocol PubMed NCT00777036
Nilotinib monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
(CAMN107A2120) | 2011-NR | Phase 1, <20 pts (RT) |
Note: there is no obvious publication of this trial.
Targeted therapy
References
- CAMN107A2120: NCT01077544